{"transactions":[{"id":997672,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":73059,"kind":"person","name":"Nelabhotla Venkateswarlu","position":1,"cik":"0002083546","reported_name":"Nelabhotla Venkateswarlu","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T00:35:03.000Z","date":"2025-11-13","kind":"grant","planned":false,"acquired":true,"shares":615149,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer (\"Merger Sub\"), and Vyome Therapeutics, Inc. (\"Vyome Therapeutics\"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the \"Merger\"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed \"Vyome Holdings, Inc.\" and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc."},{"field":"security","element":"securityTitle","label":"F2","text":"Pursuant to the Merger Agreement the reporting person was granted options to purchase 615,149 shares of the Issuer's common stock, all of which were fully vested as of the grant date. The options were granted under the Issuer's 2025 Equity Incentive Plan."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer (\"Merger Sub\"), and Vyome Therapeutics, Inc. (\"Vyome Therapeutics\"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the \"Merger\"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed \"Vyome Holdings, Inc.\" and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement the reporting person was granted options to purchase 615,149 shares of the Issuer's common stock, all of which were fully vested as of the grant date. The options were granted under the Issuer's 2025 Equity Incentive Plan."}],"balance_after":615149,"derivative":{"exercise_price":0.66,"exercise_date":"2025-11-13","expiration_date":"2035-07-30","underlying":"Common Stock","underlying_shares":615149},"source":{"system":"sec-edgar","filing":"0001213900-25-111681","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000121390025111681/ownership.xml","form_type":"4"}},{"id":1034429,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":73059,"kind":"person","name":"Nelabhotla Venkateswarlu","position":1,"cik":"0002083546","reported_name":"Nelabhotla Venkateswarlu","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-09-22T21:24:22.000Z","date":"2025-08-15","kind":"grant","planned":false,"acquired":true,"shares":7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer (\"Merger Sub\"), and Vyome Therapeutics, Inc. (\"Vyome Therapeutics\"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the \"Merger\"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed \"Vyome Holdings, Inc.\" and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 7 shares of the Issuer's common stock in exchange for 35,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer (\"Merger Sub\"), and Vyome Therapeutics, Inc. (\"Vyome Therapeutics\"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the \"Merger\"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed \"Vyome Holdings, Inc.\" and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 7 shares of the Issuer's common stock in exchange for 35,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement."}],"balance_after":7,"source":{"system":"sec-edgar","filing":"0001213900-25-090188","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000121390025090188/ownership.xml","form_type":"4"}}]}